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Risk Factors for Recurrence of Atrial Fibril lation in Horses After
Cardioversion to Sinus Rhythm
A. Decloedt, C.C. Schwarzwald, D. De Clercq, N. Van Der Vekens, B. Pardon, V.B. Reef *, and G. van
Loon *
Background: Although atrial ﬁbrillation (AF) can be successfully treated in horses, recurrence occurs frequently. In
humans, atrial function after cardioversion can predict recurrence.
Objectives: To examine the prognostic value of atrial mechanical function at 24 hours after cardioversion and other
potential predictor variables for AF recurrence in horses.
Animals: 117 horses treated for AF at 4 referral centers.
Methods: Retrospective study. Inclusion criteria were successful cardioversion, echocardiography at 24 hours after cardio-
version and ≥4 months follow-up. To determine factors associated with AF recurrence, a multivariable survival model was
built.
Results: 133 AF episodes in 117 horses were included. AF recurred in 36/100 horses with a ﬁrst AF episode and in 57/
133 AF episodes overall. Factors associated with recurrence in horses with a ﬁrst episode were previous unsuccessful treat-
ment attempt (hazard ratio HR 2.36, 95% conﬁdence interval CI 1.11–4.99, P = .025) and mild or moderate mitral regurgita-
tion (HR 2.70, 95% CI 1.23–5.91, P = .013). When the last AF episode of all horses was included, previous AF (HR 2.53,
1.33–4.82, P = .005) and active left atrial fractional area change ≤9.6% (HR 3.43, 1.22–9.67, P = .020) were signiﬁcant pre-
dictors.
Conclusions and Clinical Importance: The only echocardiographic variable of left atrial function with signiﬁcant prognos-
tic value for recurrence was low active left atrial fractional area change. Further research is necessary to evaluate whether
echocardiography at a later timepoint could provide more prognostic information.
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Atrial ﬁbrillation (AF) is the most importantarrhythmia causing poor performance in horses.1
Heart rates 40–60 beats/minute higher than expected
for the work performed are common in horses with AF,
resulting in an important performance decrease at peak
exercise. In horses performing rigorous work, cardiover-
sion is desirable.1 In horses used for less intense athletic
work, cardioversion is advised if horses have dispropor-
tionate tachycardia, QRS broadening or R-on-T phe-
nomenon during exercise, because of the potential risk
of these arrhythmias for exercise-associated weakness,
collapse, or even death.2 Over the past decades, diﬀer-
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a maximal atrial contraction
Aduration Apeak duration by tissue Doppler imaging
AF atrial ﬁbrillation
AosxA aortic internal area in short-axis view
AosxD aortic internal diameter in short-axis view
Apeak peak atrial contraction velocity by tissue Doppler
imaging
CI 95% conﬁdence interval
diast end ventricular diastole, one frame after mitral valve
closure
FACLAact active LA fractional area change
FACLApas passive LA fractional area change
FSLAact active LA fractional shortening
HR hazard ratio
LA left atrium
LAA LA area in four-chamber view
LAD maximal LA diameter in four-chamber view
LAsxA LA area in short-axis view
LAsxD LA internal diameter in short-axis view
p at onset P
PW pulsed wave
QG quinidine gluconate
QS quinidine sulfate
SD standard deviation
Syst end ventricular systole, one frame before mitral valve
opening
tAonset time from onset electrocardiographic P wave to onset
Apeak by tissue Doppler imaging
tApeak time from onset electrocardiographic P wave to Apeak
by tissue Doppler imaging
TDI tissue Doppler imaging
TVEC transvenous electrical cardioversion
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ent treatment options have been described. Medical
treatment can be performed using quinidine sulfate
(QS) administered via nasogastric intubation or quini-
dine gluconate (QG) administered IV. The use of amio-
darone or ﬂecainide has also been described although
the success rate for conversion of naturally occurring
AF using amiodarone (58%) and ﬂecainide (10%) is
rather low and treatment with ﬂecainide can cause dan-
gerous ventricular dysrhythmias. Therefore, these treat-
ments are not routinely used.3–8 Quinidine sulfate
administered via nasogastric intubation has a success
rate of 70–89%.5,9–11 Cases can also be treated by trans-
venous electrical cardioversion (TVEC), with a reported
success rate of 94–99%.12–14 However, no direct com-
parison between cardioversion methods can be made
from data in literature as the case populations diﬀer
between studies.
Atrial contractile dysfunction is evident after cardio-
version of experimental and naturally occurring AF in
horses, likely because of AF-induced atrial remodel-
ing.15–17 Atrial myocardial remodeling protects the car-
diomyocytes against intracellular Ca2+ overload caused
by the high ﬁbrillatory rate during AF. Electrical, con-
tractile, and structural remodeling and reverse remodel-
ing after cardioversion occurs in goats and dogs with
experimental disease.18 After cardioversion in horses
there is a gradual improvement of atrial contractile
function measured by 2D echocardiography and tissue
Doppler imaging (TDI).19 In human medicine, TDI-
based left atrial electromechanical conduction time after
cardioversion of AF is a predictor of 6-month sinus
rhythm maintenance.20 In horses, AF recurrence occurs
in 15–40% after successful treatment.9–12,21,22 Recur-
rence rate is independent of treatment modality but
inﬂuenced by AF duration, atrial size and electrophysi-
ological properties.9,22 However, a large multicenter
study on AF recurrence in horses including diﬀerent
treatment methods and measurements of atrial contrac-
tile function is currently lacking.
The primary aim of this study was to determine
whether echocardiography at 24 hours after cardiover-
sion could be used to predict AF recurrence in horses
successfully treated for AF. In addition, signalment, AF
history, cardiac comorbidities such as valvular regurgi-
tation, method of treatment, and administration of
drugs at or after cardioversion were included as poten-
tial prognostic factors.
Materials and Methods
Study Set-up
A retrospective multicenter study was performed to determine
the risk of recurrence after AF cardioversion and associated risk
factors. At 4 university referral centers, namely Ghent University
(Belgium), New Bolton Center (University of Pennsylvania, USA),
University of Zurich (Switzerland) and The Ohio State University
(USA), clinical records of horses admitted between January 2005
and May 2013 were retrospectively reviewed for AF cases. Inclu-
sion criteria were successful cardioversion, availability of digitally
stored echocardiographic recordings suitable for assessment of left
atrial mechanical function performed 24 hours after cardioversion
and after at least 4 months follow-up. Based on the history, racing
performance and previous examinations by the local veterinarian,
AF duration was estimated and previous AF episodes and treat-
ment attempts were recorded. Follow-up was performed by tele-
phone contact with the horse owners, trainers, or local
veterinarians or by follow-up visits to the clinic. Recurrence was
deﬁned as the presence of an irregular rhythm consistent with AF
detected by cardiac auscultation or AF conﬁrmed by ECG. The
follow-up time was deﬁned as the time to recurrence or in horses
without recurrence as the time period until the date of interview
with the owner or the last veterinary examination.
Echocardiography
In all horses, echocardiography had been performed 24 hours
after cardioversion using a similar ultrasound system in the diﬀer-
ent centers. Oﬄine analysis was performed by a single observer
(A.D.) using dedicated software. Measurements included a classiﬁ-
cation of valvular regurgitation, 2D echocardiographic measure-
ments of left atrial (LA) size and function and tissue Doppler
(TDI) measurements of LA function.15,19,23,24 A detailed descrip-
tion of the imaging and analysis protocol is available online as
Data S1.
Statistics
Data are reported as mean  standard deviation (SD) for nor-
mally distributed data or as median (range) for nonnormally dis-
tributed data. The underlying assumptions of normality were
checked by visual inspection of the raw data plots and by using
the Shapiro-Wilk test of linearity and Kolmogorov-Smirnov test
of sample cumulative distribution.a To determine factors signiﬁ-
cantly associated with the hazard of AF recurrence, two survival
models were built. In a ﬁrst model, only horses with a ﬁrst AF epi-
sode were included. Predictor variables of interest were: body
weight, age, sex, breed (Warmblood, Standardbred or trotter,
Thoroughbred, other), use (racing or other), referral center, previ-
ous unsuccessful treatment attempt (0/1), previous AF (0/1), AF
duration, valvular regurgitation when in atrial ﬁbrillation (none,
trivial, mild, moderate), method of treatment (medical or electri-
cal), total dose of quinidine administered, total J administered dur-
ing TVEC, administration of amiodarone, digoxin, or other
antiarrhythmic drugs at cardioversion, administration of ACE-
inhibitors, digoxin, dexamethasone or KCl supplementation after
cardioversion and the echocardiographic variables measured at
24 hours after cardioversion (Table 1). The group of horses with
moderate mitral regurgitation was subsequently pooled with the
group with mild mitral regurgitation after it was determined that
mild mitral regurgitation was a signiﬁcant predictor of recurrence.
Interactions between predictor variables were examined using chi-
square tests for categorical variables, independent t-tests for com-
paring continuous normally distributed variables in 2 groups or a
one-way analysis of variance with post-hoc Bonferroni correction
for comparing continuous normally distributed variables in 3 or
more groups. Nonnormally distributed data were compared using
the Mann-Whitney U-test. Initially, all predictors were tested uni-
variably and hazard ratios (HR) and 95% conﬁdence intervals
(CI) were calculated (Cox proportional hazards model). Those pre-
dictors with P < .20 were withheld for multivariable analysis. Pos-
sible associations between these predictor variables were explored
by the chi-square test for categorical variables and by Pearson r
and Spearman’s rs correlations for continuous variables. For vari-
ables with over 60% correlation, only the variable which was most
signiﬁcantly associated with recurrence was included in the multi-
variable model. This multivariable Cox regression model was built
by stepwise backward selection, gradually excluding nonsigniﬁcant
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variables. Wald’s test was used to assess parameter estimate signiﬁ-
cance. Final model variable pair-wise interactions were evaluated
and compliance with the assumptions of proportional hazard mod-
els was checked by log cumulative hazard plots and Schoenfeld
residuals. Kaplan-Meier survival curves were generated to visualize
possible associations between the studied factors and recurrence.
The follow-up time was used as time variable and AF recurrence
was used as outcome variable. Horses with loss of follow-up were
right censored at the time of last conﬁrmed AF absence. Continu-
ous variables were both analysed as a continuous variable and as
a categorical factor. Categories were based on quartiles. If an ordi-
nal increase or decrease in the hazard was present with each quar-
tile, these parameters were taken forward as continuous. If 1 or
more quartiles had signiﬁcantly diﬀerent survival curves, these
variables were taken forward as categorical data using cut-oﬀs
based on the values of the diﬀering quartile(s).
To determine whether horses which already experienced an AF
recurrence have a higher risk for AF recurrence after cardiover-
sion, a second multivariable survival model was built using the last
AF episode of all horses in the database. The HR and 95% CI
were calculated (Cox proportional hazards model). In the multi-
variable models, signiﬁcance was set at P < .05.
Results
The study included 133 AF episodes that were suc-
cessfully converted in 117 horses. A detailed description
of the study population including AF history and treat-
ment methods is available online as Supplementary
Information (Data S1).
The echocardiographic measurements are listed in
Table 1. Color and PW TDI measurements were avail-
able in 80/133 cases and 72/133 cases respectively.
Atrial contractile function based on 2DE (ie FSLAact,
FACLAact) and TDI variables was impaired compared
to the normal reference range.19,24
In the group of horses with a ﬁrst AF episode, horses
treated by TVEC showed a signiﬁcantly higher body-
weight, age, and AF duration compared to horses trea-
ted medically (Table S1). The left atrial dimensions,
time to Apeak by color TDI and time to onset Apeak by
color TDI were also signiﬁcantly higher (Table S1).
Several other interactions between risk factors were
present. AF duration was signiﬁcantly shorter in race-
horses (median 21 days, range 2–365) compared to
other breeds (median 105 days, range 5–720,
P < .001). Similarly, signiﬁcant interactions between
referral center, breed, AF duration, and drug treatment
were present. Over all episodes, 69% of medical treat-
ments and only 18% of TVEC treatments were per-
formed in racehorses compared to Warmbloods and
other breeds. 82% of TVEC treatments were performed
at Ghent University and 75% of medical treatments at
the New Bolton Center. Amiodarone was exclusively
used in Warmbloods, while digoxin was mainly used in
Standardbreds and trotters. Horses with mild or moder-
ate mitral regurgitation were predominantly Warmblo-
ods (69%) and showed signiﬁcantly larger left atrial
dimensions compared to horses without and with trivial
mitral regurgitation (Table S2).
The recurrence rate, median time to recurrence and
median follow-up time are listed in Table 2. Factors
univariably associated with an increased hazard of AF
recurrence were a previous unsuccessful treatment
attempt, mitral regurgitation, higher total dose of quini-
dine administered, FACLAact ≤9.6%, higher FACLApas,
and lower FSLAact (P < .20, Table 3, Fig. 1–2). These
factors did not show high correlation with each other
and were therefore all included in the multivariable
model. All other factors were not signiﬁcantly associ-
ated with recurrence.
In the multivariable proportional hazards model
based on 100 observations including only horses with a
ﬁrst AF episode, previous unsuccessful treatment
attempt (HR 2.36, 95% CI 1.11–4.99, P = .025) and
mild or moderate mitral regurgitation (HR 2.70, 95%
CI 1.23–5.91, P = .013) were associated with recurrence.
In the multivariable proportional hazards model includ-
ing the last AF episode of 117 horses, previous AF (HR
Table 1. Echocardiographic measurements of left
atrial dimensions and atrial function in 133 AF episodes
at 24 hours postcardioversion.
Mean SD N Reference range*
Heart rate (bpm) 42 7 133 37  5
LADdiast (cm) 11.9 1.3 126 9.9  0.8
LADsyst (cm) 12.7 1.2 126 11.3  0.7
LADp (cm) 11.7 1.2 126 10.6  0.7
LADa (cm) 11.1 1.2 126 9.3  0.7
FSLAact (%) 5.2 2.5 126 12.3  2.1
LAAdiast (cm2) 90.0 18.2 126 65.0  9.1
LAAsyst (cm2) 108.9 20.3 126 87.5  9.9
LAAp (cm2) 85.8 16.9 126 69.9  8.9
LAAa (cm2) 79.6 16.2 126 57.8  8.0
FACLAact (%) 7.3 3.3 126 17.4  2.9
FACLApas (%) 21.1 4.4 126 20.1  3.1
LAsxD (cm) 10.2 0.92 111 9.5  0.7
LAsxD/AosxD 1.4 0.13 111 1.4  0.09
LAsxA (cm
2) 126.0 21.0 111 102.1  13.2
LAsxA/AosxA (cm
2) 2.5 0.40 111 2.4  0.28
color TDI Apeak (cm/s) 2.1 1.2 80 4.3  1.3
color TDI tApeak (ms) 266 45 80 238  28
color TDI tAonset (ms) 200 40 80 164  24
color TDI Aduration (ms) 131 19 80 140  16
PW TDI Apeak (cm/s) 3.1 1.6 72 5.4  2.9
PW TDI tApeak (ms) 255 46 72 190  21
PW TDI tAonset (ms) 186 40 72 147  12
PW TDI Aduration (ms) 149 20 72 126  18
LAD, maximal left atrial diameter from four-chamber view; di-
ast, end-diastole; syst, end-systole; p, at onset P wave on the ECG;
a, at maximal atrial contraction; FSLAact, active left atrial frac-
tional shortening; LAA, left atrial area from four-chamber view;
FACLAact, active left atrial fractional area change; FACLApas,
passive left atrial fractional area change; LAsxD, left atrial internal
diameter at end ventricular systole from short-axis view; LAsxD/
AosxD, ratio of left atrial to aortic internal diameter at end ven-
tricular systole; LAsxA, left atrial area at end ventricular systole
from short-axis view; LAsxA/AosxA, ratio of left atrial to aortic
area; Apeak, peak velocity during atrial contraction; tApeak, time
from onset P to Apeak; tAonset, time from onset P to onset Apeak;
Aduration, Apeak duration.
*Based on previous publications19,24 and unpublished data
(FACLApas-in 37 horses, age 8  4 years, body weight
552  58 kg).
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2.53, 1.33–4.82, P = .005, Fig. 3) and FACLAact ≤9.6%
(HR 3.43, 1.22–9.67, P = .020, Fig. 4) were signiﬁcant
predictors of recurrence. In horses with a second AF
episode, the recurrence rate was 36.4% at 4 months and
52.6% at 1 year.
Discussion
This multicenter study describes the outcome of 133
successful AF cardioversions. A multivariable propor-
tional hazards model identiﬁed previous unsuccessful
treatment attempt and mitral regurgitation as factors
associated with recurrence in horses treated for a ﬁrst
AF episode. Considering the risk factors present at the
last AF episode, previous AF and atrial contractile dys-
function at 24 hours after cardioversion, assessed by 2D
echocardiography, were identiﬁed as predictors of recur-
rence.
The cases described reﬂect the caseload of the centers
involved in the study, as the study was in all centers
part of prospective studies investigating atrial contrac-
tile dysfunction after cardioversion.16,19 Therefore, all
consecutive cases admitted for cardioversion were
included in the study if they met the inclusion criteria.
However, these criteria might have introduced a selec-
tion bias. Horses with AF recurrence within 24 hours
after cardioversion were excluded from the analysis as
no 24 hour echocardiography in sinus rhythm was
available. AF horses which were not treated because of
expected high risk of recurrence were also not included,
such as horses with moderate to severe mitral regurgita-
tion and associated LA dilatation.
The recurrence rate of 39% at 1 year after cardiover-
sion in horses with a ﬁrst AF episode is higher com-
pared to reported recurrence rates in earlier studies,
although a recurrence rate of 45% has previously been
reported in horses with an AF duration longer than
1 month.5,9–12,21,22 The majority of horses in our study
were Warmbloods with long AF duration, which might
explain the higher recurrence rate, although breed, use
and AF duration were not signiﬁcantly associated with
recurrence.
However, the multivariable model could have been
inﬂuenced by interdependence of the various risk factors.
For example, AF duration was signiﬁcantly longer in
Warmbloods compared to racehorses. In addition, AF
duration was estimated based on the time of diagnosis by
the local veterinarian or the onset of signs noted by rider
or driver. These signs are often subtle in Warmbloods
and thus AF duration might have been underestimated.2
In the multivariable proportional hazards model includ-
ing the last AF episode of 117 horses, the eﬀect of AF
duration could be masked as owners will recognize the
disease earlier in a horse with recurrent AF. However,
AF duration was also not associated with recurrence in
the model including only horses with a ﬁrst AF episode.
Table 2. Recurrence rate and median, minimum and maximum time to recurrence and time of follow-up in all 133
AF episodes and in 100 ﬁrst AF episodes.
Recurrence All cases (n = 133) First AF episodes (n = 100)
At 4 months Recurrence 30 (22.6%) 20 (20.0%)
No recurrence 103 80
At 1 year Recurrence 47 (42.7%) 32 (39.0%)
No recurrence 63 50
Unknown 23 18
Overall Recurrence 57 (42.9%) 36 (36.0%)
Time to recurrence (days) 113 (3–1427) 113 (3–1427)
No recurrence 76 64
Follow-up time (days) 510 (123–2403) 544 (123–2403)
Table 3. Univariable predictors of recurrence in 100 horses successfully treated for a ﬁrst episode of atrial ﬁbrilla-
tion.
Factor Level n HR 95% CI P value
Previous unsuccessful treatment attempt None 81 Reference
≥1 19 2.06 0.99–4.27 0.054
Mitral regurgitation None 40 Reference
Trivial 30 1.08 0.44–2.66 0.88
Mild or moderate 30 2.67 1.22–5.84 0.015
Total quinidine (g) (per unit increase in 1 g) 1.02 1.00–1.04 0.10
FACLAact >9.6% 22 Reference
≤9.6% 73 2.72 0.96–7.70 0.061
FACLApas (%) (per unit increase in 1%) 1.09 1.01–1.18 0.030
FSLAact (%) (per unit increase in 1%) 0.91 0.80–1.05 0.19
HR, hazard ratio; FSLAact, active left atrial fractional shortening; LAA, left atrial area from four-chamber view; FACLAact, active left
atrial fractional area change; FACLApas, passive left atrial fractional area change.
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The treatment method (electrical versus medical) was
not associated with recurrence. However, the study
setup did not fully permit comparison as the treatment
method was not randomized but instead reﬂected the
clinicians’ preference and typical case population. Quin-
idine was more often used for horses with short dura-
tion AF and racehorses, whereas TVEC was more often
used in Warmbloods, horses with long duration AF or
horses where previous QS treatment had failed. In 23/
133 cases, a previous treatment attempt was reported.
In 15 cases, this was unsuccessful medical treatment fol-
lowed by successful TVEC. Higher success rates of
TVEC have been reported in literature, although no
direct comparison is available.9–12,12–14 Antiarrhythmic
Fig 2. Kaplan–Meier survival curve for horses with a ﬁrst episode
of AF, with and without a previous unsuccessful treatment
attempt for cardioversion of AF (n = 100). Proportion of horses
without AF recurrence.
Fig 3. Kaplan–Meier survival curve for horses with a ﬁrst AF
episode or with previous AF, including the last AF episode of all
horses (n = 117). Proportion of horses without AF recurrence.
Fig 4. Kaplan–Meier survival curve for horses with an active left
atrial fractional area change in ≤9.6% or >9.6%, including the last
AF episode of all horses (n = 117). Proportion of horses without
AF recurrence.
Fig 1. Kaplan–Meier survival curve for horses with a ﬁrst episode
of AF, with no, trivial and mild or moderate mitral regurgitation
(n = 100). Proportion of horses without AF recurrence.
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drugs were more frequently used in horses deemed more
prone to recurrence by the clinician. This interdepen-
dence of various factors might have inﬂuenced the
results of the multivariable model for predicting recur-
rence, especially concerning the eﬀect of treatment.
We hypothesized that horses with more severe atrial
contractile dysfunction at 24 hours after cardioversion
would be more prone to recurrence. This time point
was chosen as it was deemed to have most clinical
applicability. Follow-up at a later time is often not fea-
sible under clinical circumstances. However, the major
limitation of echocardiography at 24 hours after cardio-
version is the interference with antiarrhythmic drugs.
QS shows a long and variable half-life in horses so low
plasma concentrations can be expected at 24 hours.25
QS plasma levels at the time of echocardiography were
available in only 6 horses, in which low concentrations
were found. The negative inotropic properties of QS
have been documented in vivo in several species and are
dose-dependent.26,27 The potential inﬂuence of occur-
rence and severity of adverse quinidine eﬀects was not
considered within the scope of this study. The measure-
ments at 24 hours could also be inﬂuenced by other
antiarrhythmic drugs, such as amiodarone. Amiodarone
shows few negative inotropic eﬀects and even showed a
positive inotropic eﬀect at high concentrations on iso-
lated atrial cardiomyocytes.28 Amiodarone is highly
lipophilic with a high volume of distribution and long
elimination half-life. After a single intravenous dosage,
the myocardial concentration decreases quickly when
amiodarone is redistributed to fat but a secondary peak
in plasma concentrations several hours after administra-
tion might be present because of entero-hepatic
cycling.29,30 The inﬂuence of TVEC treatment without
drug administration on myocardial function is
unknown, but no increase in cardiac troponin I levels
could be detected at 24 hours after cardioversion in 72
AF episodes.12 Echocardiography at 24 hours after car-
dioversion demonstrated atrial contractile dysfunction
based on 2D echocardiography (ie FSLAact, FACLAact)
and TDI variables, similar to that previously
reported.15,16,19
The factors univariably associated with recurrence in
horses with a ﬁrst AF episode were related to atrial
function (FACLApas, FACLAact, and FSLAact), ease of
treatment (previous unsuccessful treatment attempt and
total quinidine administered) and presence of mitral
regurgitation. FACLApas is related to left ventricular
early diastolic ﬁlling. In man, this parameter decreases
with age and mitral valve stenosis, whereas early dia-
stolic ﬁlling is increased in case of mitral regurgita-
tion.31,32 The lower FACLAact and FSLAact associated
with recurrence reﬂect atrial contractile dysfunction. In
human medicine, patients with AF recurrence showed
deteriorated atrial mechanical function compared to
patients in sinus rhythm after 1 month.33 Left atrial
electromechanical conduction time was included in our
study as the time to onset and peak A measured by
TDI. In our study, the time to onset A and peak A was
prolonged at 24 hours after cardioversion compared to
reference values.19 This might be explained by larger
atrial size or slower conduction caused by electrical
remodelling. However, this variable did not show prog-
nostic value. In man, this variable is a prognostic factor
for AF recurrence as well as a predictor for new onset
AF.20,34,35 This might either be explained by the diﬀer-
ent pathophysiology of AF in human compared to
horses or by the fact that echocardiography at 24 hours
after cardioversion might be too early to detect diﬀer-
ences in reverse remodeling.
The signiﬁcant association between a previous unsuc-
cessful treatment attempt and recurrence might suggest
diﬀerences in atrial electrophysiology or the presence of
underlying atrial myocardial disease in these horses. It
has been demonstrated experimentally that atrial elec-
trophysiological remodeling occurs during AF in
horses.15,36,37 These factors might provide a substrate
for AF induction and maintenance. In addition to an
AF substrate, triggers such as atrial premature depolar-
izations are needed for AF induction.1 No ECG data
were included in this study, although the presence of
atrial premature depolarizations in the postcardiover-
sion period might also be an important prognostic fac-
tor.
Mild or moderate mitral regurgitation was withheld
as a prognostic factor in the multivariable model. If
only mild mitral regurgitation was considered, a signiﬁ-
cantly higher recurrence rate was also found compared
to none or trivial regurgitation. Mitral regurgitation
induces atrial myocardial stretch and has previously
been associated with AF in horses.38 Chronic atrial
stretch because of pressure and volume overload leads
to changes in the cellular signaling pathways and the
composition of interstitial matrix, thereby promoting
atrial dilatation and AF in humans, dogs, rats, and pre-
sumably horses.18
A study limitation was that no echocardiographic
measurements during AF were included. These might
diﬀer from measurements after cardioversion and would
be useful in providing prognostic information before
cardioversion is attempted. However, measurements
during AF are diﬃcult because of the large RR interval
variations which inﬂuence cardiac diameters. In addi-
tion, the goal was to determine whether atrial contrac-
tile dysfunction had prognostic value. While
echocardiography at 24 hours after cardioversion might
be too early for reliably predicting AF recurrence, echo-
cardiography in the ﬁrst days to weeks after cardiover-
sion might still be valuable as a prognostic indicator by
identifying those horses with slow atrial functional
recovery or to determine the period of rest before
returning to exercise.19 However, this was outside the
scope of this study. The reliability of echocardiographic
measurements might have been increased by using a
higher number of nonconsecutive cardiac cycles in all
horses.39 In most horses, three consecutive cardiac
cycles were measured as this has been shown in a previ-
ous study to yield repeatable results.19 Finally, no infor-
mation was included on physical activity during the
follow-up period as this was highly variable and could
not be reliably recorded to include in the model. There-
fore, we have no information on the inﬂuence of
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exercise on recurrence. Despite these limitations, the
study population and study design reﬂected a realistic
clinical scenario, in which not all factors can be con-
trolled and interactions between diﬀerent factors are
inevitable.
Conclusions
After successful treatment of a ﬁrst AF episode in
horses, recurrence occurs in 39% at one year after car-
dioversion. In horses with a ﬁrst AF episode, previous
unsuccessful treatment attempt and mitral regurgitation
were identiﬁed as risk factors for recurrence in a multi-
variable model. When horses with recurrent AF were
included, previous AF and low active left atrial frac-
tional area change observed at 24 hours after cardiover-
sion were risk factors for recurrence in a multivariable
model. Other echocardiographic measurements also
demonstrated atrial contractile dysfunction but were
not signiﬁcant risk factors in the proportional hazards
model. However, because of the limitations of this ret-
rospective study, further research is necessary to evalu-
ate whether echocardiography at a later time point
could provide more prognostic information.
Footnote
a SPSS Statistics 21.0.0., SPSS Inc, Chicago, IL
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Supporting Information
Additional Supporting Information may be found
online in Supporting Information:
Table S1. Comparison of signalment, AF duration,
heart rate and echocardiographic variables measured
24 hours after successful cardioversion in horses with a
ﬁrst atrial ﬁbrillation (AF) episode treated by transve-
nous electrical cardioversion (n = 56) or by medical
(quinidine) cardioversion (n = 44).
Table S2. Comparison of signalment, AF duration,
heart rate, and echocardiographic variables measured
24 hours after successful cardioversion in horses with
no MR (n = 48), horses with trivial MR (n = 34) and
horses with mild or moderate mitral regurgitation (MR)
(n = 35).
Data S1. Supplementary information regarding meth-
odology (imaging and analysis protocol) and results
(detailed description of the study population including
AF history and treatment methods).
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